Home > Dermatology > EADV 2020 > Late-Breaking News > Light at the end of the tunnel for chronic hand eczema

Light at the end of the tunnel for chronic hand eczema

Presented By
Prof. Margitta Worm, Prof. Howard Sofen
EADV 2020
Phase 2
Both topical and oral JAK inhibitors led to rapid and sustained improvement in skin status in patients with chronic hand eczema, an indication with limited therapeutic options. In two phase 2b trials, delgocitinib, a topical pan-JAK inhibitor, and gusacitinib, and oral JAK inhibitor, demonstrated remarkable efficacy and a fast onset of action in hand eczema [1,2]. Hand eczema is characterised by painful, pruritic, non-infectious inflammatory skin changes on the hands and wrist. The disease is considered chronic when it lasts ≥3 months or relapses at least twice a year. Current topical treatment options are limited to emollients, topical corticosteroids, and calcineurin inhibitors. The novel, topical pan-JAK inhibitor delgocitinib prevents inflammation by blocking several cytokine-mediated signalling cascades involved in the pathophysiology of chronic hand eczema. This explains the motivation for a recent phase 2b, dose-finding study in chronic hand...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on